AIMS: LDL cholesterol (LDL-C) is the current lipid standard for cardiovascular disease (CVD)-risk assessment in type 1 diabetes. Apolipoprotein B (apoB) may be helpful to further stratify CVD risk. We explored the association between apoB and pulse wave velocity (PWV) to determine if apoB would improve CVD-risk stratification, especially in type 1 diabetes adolescents with borderline LDL-C (100-129 mg/dL). We hypothesized that type 1 diabetes adolescents with borderline LDL-C and elevated apoB (≥90 mg/dL) would have increased PWV compared to those with borderline LDL-C and normal apoB (<90 mg/dL), and that apoB would explain more of the variability of PWV than alternative lipid indices. METHODS: Fasting lipids, including apoB, were collected in 267 adolescents, age 12-19 years, with diabetes duration >5 years and HbA1c 8.9 ± 1.6 %. Triglyceride to HDL-C ratio (TG/HDL-C) and nonHDL-cholesterol (nonHDL-C) were calculated. PWV was measured in the carotid-femoral segment. RESULTS: ApoB, nonHDL-C and TG/HDL-C correlated with PWV (p < 0.0001). ApoB, nonHDL-C and TG/HDL-C remained significantly associated with PWV in fully adjusted models. In adolescents with borderline LDL-C (n = 61), PWV was significantly higher in those with elevated apoB than in those with normal apoB (5.6 ± 0.6 vs. 5.2 ± 0.6 m/s, p < 0.01) and also remained significant after adjustment for CVD-risk factors (p = 0.0002). Moreover, in those with borderline LDL-C, apoB explained more of the variability of PWV than nonHDL-C and TG/HDL-C. CONCLUSION: Elevated apoB is associated with increased arterial stiffness in type 1 diabetes adolescents. Measurement of apoB in addition to LDL-C may be helpful in stratifying CVD risk in type 1 diabetes adolescents, especially in those with borderline LDL-C.
AIMS: LDL cholesterol (LDL-C) is the current lipid standard for cardiovascular disease (CVD)-risk assessment in type 1 diabetes. Apolipoprotein B (apoB) may be helpful to further stratify CVD risk. We explored the association between apoB and pulse wave velocity (PWV) to determine if apoB would improve CVD-risk stratification, especially in type 1 diabetes adolescents with borderline LDL-C (100-129 mg/dL). We hypothesized that type 1 diabetes adolescents with borderline LDL-C and elevated apoB (≥90 mg/dL) would have increased PWV compared to those with borderline LDL-C and normal apoB (<90 mg/dL), and that apoB would explain more of the variability of PWV than alternative lipid indices. METHODS: Fasting lipids, including apoB, were collected in 267 adolescents, age 12-19 years, with diabetes duration >5 years and HbA1c 8.9 ± 1.6 %. Triglyceride to HDL-C ratio (TG/HDL-C) and nonHDL-cholesterol (nonHDL-C) were calculated. PWV was measured in the carotid-femoral segment. RESULTS:ApoB, nonHDL-C and TG/HDL-C correlated with PWV (p < 0.0001). ApoB, nonHDL-C and TG/HDL-C remained significantly associated with PWV in fully adjusted models. In adolescents with borderline LDL-C (n = 61), PWV was significantly higher in those with elevated apoB than in those with normal apoB (5.6 ± 0.6 vs. 5.2 ± 0.6 m/s, p < 0.01) and also remained significant after adjustment for CVD-risk factors (p = 0.0002). Moreover, in those with borderline LDL-C, apoB explained more of the variability of PWV than nonHDL-C and TG/HDL-C. CONCLUSION: Elevated apoB is associated with increased arterial stiffness in type 1 diabetes adolescents. Measurement of apoB in addition to LDL-C may be helpful in stratifying CVD risk in type 1 diabetes adolescents, especially in those with borderline LDL-C.
Authors: J Mancera-Romero; M A Sánchez-Chaparro; J Rioja; M J Ariza; G Olivecrona; P González-Santos; P Valdivielso Journal: Acta Diabetol Date: 2012-10-09 Impact factor: 4.280
Authors: A R Sharrett; C M Ballantyne; S A Coady; G Heiss; P D Sorlie; D Catellier; W Patsch Journal: Circulation Date: 2001-09-04 Impact factor: 29.690
Authors: Elaine M Urbina; Philip R Khoury; Connie E McCoy; Lawrence M Dolan; Stephen R Daniels; Thomas R Kimball Journal: Pediatrics Date: 2013-03-04 Impact factor: 7.124
Authors: John J Albers; April Slee; Kevin D O'Brien; Jennifer G Robinson; Moti L Kashyap; Peter O Kwiterovich; Ping Xu; Santica M Marcovina Journal: J Am Coll Cardiol Date: 2013-08-21 Impact factor: 24.094
Authors: Jamie R Wood; Kellee M Miller; David M Maahs; Roy W Beck; Linda A DiMeglio; Ingrid M Libman; Maryanne Quinn; William V Tamborlane; Stephanie E Woerner Journal: Diabetes Care Date: 2013-01-22 Impact factor: 19.112
Authors: Elaine M Urbina; Scott Isom; Ronny A Bell; Deborah A Bowlby; Ralph D'Agostino; Stephen R Daniels; Lawrence M Dolan; Giuseppina Imperatore; Santica M Marcovina; Anwar T Merchant; Kristi Reynolds; Amy S Shah; R Paul Wadwa; Dana Dabelea Journal: J Am Heart Assoc Date: 2019-06-19 Impact factor: 6.106
Authors: Evgenia Gourgari; Jeanette M Stafford; Ralph D'Agostino; Lawrence M Dolan; Jean M Lawrence; Amy Mottl; Catherine Pihoker; Elaine M Urbina; R Paul Wadwa; Dana Dabelea Journal: Ann Pediatr Endocrinol Metab Date: 2019-09-30